コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 u-PA is 47-fold more active than t-PA for cleavage of a
2 ino terminal fragment of u-PA inhibited 125I-u-PA binding to platelets with a mean IC50 of 65 and 58
4 membrane and of U937 cell proteins with 125I-u-PA revealed a u-PA binding protein of approximately 70
6 U937 cell proteins with 125I-u-PA revealed a u-PA binding protein of approximately 70 kD in the plate
9 -PAR) binds urokinase plasminogen activator (u-PA) and participates in plasminogen activation in addi
11 ation, urokinase-type plasminogen activator (u-PA) and u-PA receptor were observed in the immunopreci
12 genous urokinase-type plasminogen activator (u-PA) has been identified in platelet membrane, and plat
13 ity of urokinase-type plasminogen activator (u-PA) increases very rapidly (within 1 minute) after par
14 Human urokinase type plasminogen activator (u-PA) is a member of the chymotrypsin family of serine p
15 e that urokinase-type plasminogen activator (u-PA) is importantly involved in fibrinolysis, but its p
17 binds urokinase-type plasminogen activator (u-PA) through specific interactions with uPAR domain 1,
18 LN endogenous urinary plasminogen activator (u-PA), as well as by added tissue Pg Activator (t-PA), s
19 A) and urokinase-type plasminogen activator (u-PA), by modifying the technique of substrate phage dis
23 ively, our data show that in culture, active u-PA is present and cleaves scHGF to tcHGF in the contex
25 s using either a polyclonal antibody against u-PA or, since u-PA functions in the context of its rece
28 ibitor, antibodies directed against t-PA and u-PA, and epsilon-aminocaproic acid, a lysine analog tha
29 f the protease domains of two-chain t-PA and u-PA, and molecular modeling of the corresponding single
30 ary physiological inhibitor of both t-PA and u-PA, confirmed this prediction and indicated a predomin
32 kinase-type plasminogen activators (t-PA and u-PA, respectively), of their specific inhibitor (PAI-1)
34 kinase-type plasminogen activator (u-PA) and u-PA receptor were observed in the immunoprecipitates of
36 ts, we used inactive variants of trypsin and u-PA whose catalytic serine S195 had been replaced by al
38 t-PA for cleavage of a sequence known to be u-PA selective within small peptide substrates, whereas
41 the primary physiological inhibitor of both u-PA and t-PA, that inhibited u-PA approximately 70 time
42 To test whether the active, receptor-bound u-PA from the cell cultures was cleaving scHGF, iodinate
43 logical significance of receptor cleavage by u-PA, we engineered and expressed a two-chain urokinase
44 ved as much as 120 times more efficiently by u-PA than by tissue type plasminogen activator (t-PA), a
45 e cleaved 840-5300 times more efficiently by u-PA than peptides containing the physiological target s
47 r for u-PA and a portion of the single-chain u-PA (scu-PA) intrinsic to blood is tightly associated w
48 ves scu-PA to the mature protease, two-chain u-PA (tcu-PA), which is efficiently and irreversibly inh
52 echanism, as they carry a novel receptor for u-PA and a portion of the single-chain u-PA (scu-PA) int
53 dine 144 of t-PA to an acidic residue, as in u-PA, selectively suppressed the activity of single-chai
54 se in PAI-1 and TF mRNAs and the decrease in u-PA mRNA in the kidneys of MRL lpr/lpr mice suggests th
55 nhibitor-1 RNA and protein and a decrease in u-PA RNA as noted by quantitative reverse transcriptase-
56 tion to these changes in PAI-1, decreases in u-PA mRNA and increases in TF mRNA were demonstrated in
58 ibitor of both u-PA and t-PA, that inhibited u-PA approximately 70 times more rapidly than it inhibit
59 stantially more PAI-1 and substantially less u-PA were present in the atherectomy samples from subjec
60 t membrane degradation through cell-mediated u-PA activation of Pg with possible involvement of matri
66 itory activity of PAI-1 against t-PA but not u-PA suggested that the mechanism of loop insertion is s
67 report, the mechanism of the association of u-PA with platelets was investigated using recombinant,
69 eled u-PA and the amino terminal fragment of u-PA inhibited 125I-u-PA binding to platelets with a mea
70 ighly selective, high affinity inhibitors of u-PA and, consequently, may facilitate the development o
75 this study to determine whether the role of u-PA in prostate cancer induced angiogenesis and seconda
78 were labile to selective cleavage by t-PA or u-PA when in the context of a peptide were introduced in
79 o the cell in the presence of either t-PA or u-PA, conversion to Lys-Pg was observed, but conversion
80 enhanced interstitial fibrosis in Pg(-)(/-), u-PA(-)(/-), and t-PA(-)(/-) mice relative to WT and u-P
81 omycin-treated WT mice and not in Pg(-)(/-), u-PA(-)(/-), and u-PAR(-)(/-) mice or saline controls.
83 n platelets were incubated with radiolabeled u-PA, the u-PA was found to specifically and saturably b
84 a polyclonal antibody against u-PA or, since u-PA functions in the context of its receptor (u-PAR), a
86 version to tc-u-PA and incorporation into tc-u-PA.PAI complexes) in an LRP/alpha2MR-dependent manner,
87 hoblasts by facilitating the clearance of tc-u-PA.PAI complexes and regeneration of unoccupied cell s
88 UK (primarily following its conversion to tc-u-PA and incorporation into tc-u-PA.PAI complexes) in an
89 nd complexes between two-chain urokinase (tc-u-PA) and plasminogen activator inhibitor type-1 (PAI-1)
90 e upon binding to its cellular cofactor, the u-PA receptor (u-PAR), hence activating an enzymatic cas
91 al or a polyclonal antibody specific for the u-PA cell-surface receptor (u- PAR), failed to show evid
92 s were incubated with radiolabeled u-PA, the u-PA was found to specifically and saturably bind to the
93 ent, the majority was of the urokinase type (u-PA) as determined by neutralization studies using eith
95 f t-PA, however, is not shared by urokinase (u-PA), a plasminogen activator that is very closely rela
96 plasminogen activators (including urokinase (u-PA), streptokinase (SK), and tissue plasminogen activa
97 e plasminogen activator (t-PA) or urokinase (u-PA) resulted in rapid decreases of fluorescence coinci
98 her tissue Pg activator (t-PA) or urokinase (u-PA) were compared when these Pg forms were either boun
99 ient for plasminogen (Pg(-)(/-)), urokinase (u-PA(-)(/-)), urokinase receptor (u-PAR(-)(/-)), or tiss
100 Binding of the serine protease urokinase (u-PA) to its receptor on tumor cell surfaces facilitates
103 oportionate elevation of PAI-1 compared with u-PA observed in atheromatous material extracted from ve
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。